Evidence map›Paper›PMID 35880727›Full record

ArticleEndocrinology2022

Sexually Dimorphic Increases in Bone Mass Following Tissue-specific Overexpression of Runx1 in Osteoclast Precursors.

Martha Elena Díaz-Hernández, Christopher W Kinter, Shana R Watson, Giovanni Mella-Velazquez, Jarred Kaiser, Guanglu Liu, Nazir M Khan, Joseph L Roberts, Joseph Lorenzo, Hicham Drissi

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Aging · 2025
    Article
  3. Article
  4. [Latest Findings on the Role of RUNX1 in Bone Development and Disorders].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Martha Elena Díaz-HernándezDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, Georgia 30329, USA.
Christopher W KinterDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, Georgia 30329, USA.
Shana R WatsonDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, Georgia 30329, USA.
Giovanni Mella-VelazquezDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, Georgia 30329, USA.
Jarred KaiserDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, Georgia 30329, USA.
Guanglu LiuDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, Georgia 30329, USA.
Nazir M KhanDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, Georgia 30329, USA.
Joseph L RobertsDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, Georgia 30329, USA.ORCID 0000-0001-6839-1173
Joseph LorenzoDepartment of Medicine, UConn Health, Farmington, 06032, Connecticut, USA.
Hicham DrissiDepartment of Orthopaedics, Emory University School of Medicine, Atlanta, Georgia 30329, USA.ORCID 0000-0002-3322-281X
Emory University · USUConn Health · US

Funding

Runx1 Control of Bone Resorption during Fracture Repair SupplementR01AR063661 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI DRISSI, MOULAY HICHAM, LORENZO, JOSEPH A · 2013 to 2017
$1.8M
Osteogenic and angiogenic tissue regeneration to accelerate secondary bone healing during agingR01AG064464 · NIA · EMORY UNIVERSITY · PI DRISSI, MOULAY HICHAM · 2019 to 2023
$1.3M
NIAMS NIH HHS R01 AR063661NIA NIH HHS R01 AG064464
6 · The paper itself

Abstract

Many metabolic bone diseases arise as a result excessive osteoclastic bone resorption, which has motivated efforts to identify new molecular targets that can inhibit the formation or activity of these bone-resorbing cells. Mounting evidence indicates that the transcription factor Runx1 acts as a transcriptional repressor of osteoclast formation. Prior studies using a conditional knockout approach suggested that Runx1 in osteoclast precursors acts as an inhibitor of osteoclastogenesis; however, the effects of upregulation of Runx1 on osteoclast formation remain unknown. In this study, we investigated the skeletal effects of conditional overexpression of Runx1 in preosteoclasts by crossing novel Runx1 gain-of-function mice (Rosa26-LSL-Runx1) with LysM-Cre transgenic mice. We observed a sex-dependent effect whereby overexpression of Runx1 in female mice increased trabecular bone microarchitectural indices and improved torsion biomechanical properties. These effects were likely mediated by delayed osteoclastogenesis and decreased bone resorption. Transcriptomics analyses during osteoclastogenesis revealed a distinct transcriptomic profile in the Runx1-overexpressing cells, with enrichment of genes related to redox signaling, apoptosis, osteoclast differentiation, and bone remodeling. These data further confirm the antiosteoclastogenic activities of Runx1 and provide new insight into the molecular targets that may mediate these effects.

Indexed as

Bone ResorptionOsteoclastsAnimalsBone DensityCell DifferentiationCore Binding Factor Alpha 2 SubunitFemaleMiceOsteogenesisRANK LigandCore Binding Factor Alpha 2 SubunitRANK LigandRunx1 protein, mousegenetic mouse modelsosteoclastsredox balancetranscription factortranscriptomics

Identifiers

PMID35880727
PMCPMC9337273
OpenAlexW4288038557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.